FDA Lifts Clinical Hold on INmune Bio Alzheimer's Program
By Colin Kellaher
INmune Bio on Tuesday said the U.S. Food and Drug Administration has lifted the full clinical hold on the immunology company's Alzheimer's disease program.
The Boca Raton, Fla., company said a Phase 2 study using its XPro product candidate to treat patients with Alzheimer's Disease with neuroinflammation is on track to enroll its last patient in mid-2024, adding that it expects top-line data about six months after the last patient is enrolled.
The FDA implemented the clinical hold in May 2022 as the agency sought more information about XPro, but INmune has been able to continue study enrollment at sites outside the U.S.
INmune said it aims to complete the Phase 2 program this year and to hold an end-of-Phase II meeting with the FDA in early 2025 to confirm plans for a global Phase 3 study.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 30, 2024 08:42 ET (13:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
US Stock Market Outlook & Valuation for May 2024
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett